aTyr Pharma (ATYR) has received a new Buy rating, initiated by Leerink Partners analyst, Faisal Khurshid.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Faisal Khurshid has given his Buy rating due to a combination of factors, most notably the potential success of aTyr Pharma’s lead program, efzofitimod, in its Phase 3 study for pulmonary sarcoidosis. The topline results expected in the third quarter of 2025 are anticipated to be a pivotal event for the stock, supported by promising Phase 1b/2a data, simulations, expert feedback, and a thorough examination of the science behind the treatment.
Additionally, the EFZO-FIT study’s robust design, which includes a placebo-controlled setup and steroid withdrawal process, aims to effectively showcase efzofitimod’s benefits. The primary endpoint is the change in steroid use, hypothesizing that patients using efzofitimod will require less steroid intervention. Previous trial phases have shown efzofitimod’s dose-dependent efficacy and safety, with notable improvements in lung function and reduced steroid use, reinforcing the potential for a significant therapeutic impact.
In another report released on February 13, RBC Capital also maintained a Buy rating on the stock with a $16.00 price target.